Objective: Some data suggest that nocturnal rather than daytime dosing of antihypertensive agents may have benefi cial effects on consequent cardiovascular outcomes. This trial was designed to evaluate whether ABPM levels differ by timing of drug dosing, as a possible explanation for these observations. Design and Method: 103 male or female patients aged 18-80 years with ``controlled'' hypertension (≤150/≤90 mmHg) for at least three months on stable therapy of ≥1 antihypertensive agent were recruited from two centres; London and Thessaloniki. Patients were randomised to receive their usual therapy either in the morning or evening (6am-11am/6pm-11pm) for 12 weeks, then participants crossed-over to the alternative timing of drug administration for a further 12 weeks. Clinic BPs using standardised methodology and a 24 hour ABPM recording were taken at baseline, 12 and 24 weeks along with completion of the EQ-5D-5L quality of life questionnaire. The study was powered to detect 3mmHg difference in mean 24h SBP with 80% power and a=0.05 signifi cance level, and reached the target sample size. Regression model was used to calculate confi dence intervals adjusted to centre, period (visit) and sequence (group).
Results: 95 patients (92%) completed all three ABPM recordings. The mean age of recruits was 52 years and 44% were female. 24 hour systolic and diastolic BPs did not differ between daytime and nocturnal dosing (table) . Similarly, there was no impact on mean daytime (7.00am-10.00pm) or night time (10pm-7.00am) ABPM levels, nor on clinic BP levels. Stratifi cation by age (<65/≥65 years) and by gender did not affect the results.
Conclusions:
In patients with stable BP levels and hypertension diagnosed at least one year ago, the timing of antihypertensive drug administration (morning or evening) did not affect the mean 24 hour ABPM levels recorded.
[ Table - Objective: We have previously noted morning/late-morning hypotension (M/LM) in some hypertensive subjects. Here we intended to establish its prevalence in relation to daytime blood pressure (BP) in general.
Design and Method: Daytime hypotension was defi ned as systolic BP < 110mmHg or ≥25% lower than the mean 3 fi rst awake recordings provided that it was also < 85% of the mean 24h systolic-BP. We evaluated 781 ABPM (Spacelabs 90207/902017A) recordings from 179 subjects with normal BP and 602 hypertensive subjects. Clustering analysis revealed that M/LM hypotension was more prevalent, compared to other daytime hours in treated, but not in untreated hypertensive subjects (OR-1.69 and 0.87, respectively; p < 0.0005). Among treated hypertensive subjects, M/LM clustering was seen in the uncontrolled subjects (p < 0.0005) but not in controlled patients. However, daytime SP was higher in treated subjects free of daytime hypotension compared to those with falls in BP (136 ± 14 vs. 130 ± 14; t-test, p < 0.0001). SP during M/LM falls was lower in controlled than in uncontrolled hypertensive subjects (93+/-7 vs. 103+/-12 mmHg; p < 0. 0001). Age (68 ± 1.7 vs. 64 ± 1; p < 0.0001) was higher among treated subjects with M/LM falls compared with treated subjects without M/LM falls.
Results

Conclusions:
Daytime hypotensive episodes are common and tend to cluster in the M/LM hours in treated older hypertensive subjects, particularly in the setting of uncontrolled hypertension. Age, dosing time and circadian decline in hormones affecting blood pressure may play a role in this phenomenon.
LBOS 01-03 MICROALBUMINURIA IS THE MOST INTEGRATED SIGN OF SUBCLINICAL ORGAN DAMAGE IN UNCOMPLICATED HYPERTENSIVE PATIENTS
Svetlana Villevalde, Zhanna Kovbalava. Department of Cardiology, Clinical Pharmacology, Peoples' Friendship University of Russia (RUDN), Russia
Objective: Microalbuminuria (MAU) and glomerular fi ltration rate (GFR) are the signs of subclinical kidney damage, independently predict cardiovascular morbidity and mortality. The aim of the study was to investigate the relative role of MAU, cardiac and vascular ultrasonography, carotid-femoral pulse wave velocity (PWV) for the detection of hypertensive target organ damage (TOD) and risk stratifi cation.
Design and Method:
In 576 non-diabetic hypertensive patients without established cardiovascular or renal disease (291 male, 53.0 ± 10.1 years, BP 156 ± 13/99 ± 8 mmHg) MAU by albumin/creatinine urine ratio, GFR CKD-EPI , left ventricular mass index (LVMI), carotid intima-media thickness (CIMT), PWV were assessed. Spearman and multiple regression analysis were performed. P < 0.05 was considered statistically signifi cant.
Results: Prevalence of subclinical kidney damage, echo left ventricular hypertrophy (LVH), CIMT >0.9 mm and/or plaque, PVW >10 m/s was 37.5, 46.3, 23.6 and 25.7%, respectively. Different signs of TOD only partly cluster in the same group of patients. The odds ratio (OR) of a microalbuminuric patient having LVH and/ or vascular damage is 19.5 (95% CI 5-82); the OR of a patient with LVH having MAU and/or vascular damage is 7.25 (95% CI 3-16); the OR of a patient with PVW >10 m/s having MAU and/or LVH and/or carotid thickening or plaque is 3 (95% CI 1-4); the OR of a patient with CIMT >0.9 mm and/or plaque having MAU and/or LVH and/or PVW >12 m/s is 2 (95% CI 1-4). There was positive correlation between albumin/creatinine urine ratio and LVMI (r = 0.46, p < 0.001), CIMT (r = 0.38, p < 0.001), PWV (r = 0.34, p < 0.001).
Conclusions:
Microalbuminuria was the most integrated sign of TOD in uncomplicated hypertensive patients. Due availability, low cost and high predictive value combined assessment of GFR and MAU should be the fi rst step in detection of TOD for cardiovascular risk assessment. Cardiac and vascular ultrasonography for assessment of LVMI and CIMT should be performed in patients without signs of subclinical kidney damage.
